Tg Therapeutics, INC. (TGTX) — SEC Filings

Overview

Tg Therapeutics, INC. (TGTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: TG Therapeutics, Inc. reported a significant increase in net income for the nine months ended September 30, 2025, reaching $424.142 million, a substantial rise from $0.052 million in the same period of 2024. This was primarily driven by a robust increase in product revenue, net, which grew to $417.8

Sentiment Summary

Across 27 filings, the sentiment breakdown is: 2 bullish, 25 neutral. The dominant filing sentiment for Tg Therapeutics, INC. is neutral.

Filing Type Overview

Tg Therapeutics, INC. (TGTX) has filed 5 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 1 10-K/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (27)

• TG Therapeutics Soars on Revenue Growth, Tax Benefit — 10-Q · Nov 5, 2025 Risk: medium
  TG Therapeutics, Inc. reported a significant increase in net income for the nine months ended September 30, 2025, reaching $424.142 million, a substantial rise
• TG Therapeutics Files 8-K on Operations and Financials — 8-K · Nov 3, 2025 Risk: low
  On November 3, 2025, TG Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also includes financial state
• TG Therapeutics Sees Strong Revenue Growth in H1 2025 — 10-Q · Aug 8, 2025 Risk: medium
  TG Therapeutics, Inc. reported product revenue of $158,786,335 for the six months ended June 30, 2025, a significant increase from $156,204,159 for the same per
• TG Therapeutics Files 8-K: Operations & Financials — 8-K · Aug 4, 2025 Risk: low
  On August 4, 2025, TG Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition, along with financial statements and exhibi
• TG Therapeutics Files 8-K on Shareholder Votes & Financials — 8-K · Jun 13, 2025 Risk: low
  On June 12, 2025, TG Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The comp
• TG Therapeutics Q1 2025: Assets $158.7M, Liabilities $155.8M — 10-Q · May 9, 2025 Risk: medium
  TG Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $158.7 million and total liabilities of $155.8 m
• TG Therapeutics Files 8-K on Operations and Financials — 8-K · May 5, 2025 Risk: low
  On May 5, 2025, TG Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information regarding its results of operations an
• TG Therapeutics Files 2025 DEF 14A — DEF 14A · Apr 30, 2025 Risk: low
  TG Therapeutics, Inc. filed its DEF 14A on April 30, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other cor
• TG Therapeutics Files 2024 10-K — 10-K · Mar 3, 2025 Risk: medium
  TG Therapeutics, Inc. filed its 2024 10-K on March 3, 2025, reporting its fiscal year ending December 31, 2024. The company's financial statements show total as
• TG Therapeutics Files 8-K — 8-K · Jan 14, 2025 Risk: low
  TG Therapeutics, Inc. filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• TG Therapeutics Q3 2024: Assets Near Liabilities — 10-Q · Nov 7, 2024 Risk: medium
  TG Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $155,910,901 and total liabilities of $155,7
• TG Therapeutics Files 8-K on Operations and Financials — 8-K · Nov 4, 2024 Risk: low
  TG Therapeutics, Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition, and including financial statements and e
• SC 13G/A Filing — SC 13G/A · Oct 7, 2024
• TG Therapeutics Files 2023 Annual Report Amendment — 10-K/A · Aug 9, 2024 Risk: medium
  TG Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. This amendment, filed on August 9, 2024, pro
• TG Therapeutics Terminates Material Agreement — 8-K · Aug 6, 2024 Risk: medium
  On August 2, 2024, TG Therapeutics, Inc. announced the termination of its Material Definitive Agreement with a third party, effective immediately. The company a
• TG Therapeutics Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Jun 17, 2024 Risk: medium
  TG Therapeutics, Inc. filed an 8-K on June 14, 2024, reporting on several key events. These include the departure of a director, the election of new directors,
• TG Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 6, 2024 Risk: low
  TG THERAPEUTICS, INC. (TGTX) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. TG Therapeutics, Inc. reported financial results for the quarter ended
• TG Therapeutics Files 8-K Report — 8-K · May 1, 2024 Risk: low
  On May 1, 2024, TG Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, previously known as Manhattan Pharmaceuti
• TG Therapeutics, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 29, 2024 Risk: low
  TG THERAPEUTICS, INC. (TGTX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. TG Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A
• TG Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  TG THERAPEUTICS, INC. (TGTX) filed a Annual Report (10-K) with the SEC on February 29, 2024. TG Therapeutics, Inc. reported total assets of $151,465,598 as of D
• TG Therapeutics Files 8-K for Financial Update — 8-K · Feb 28, 2024 Risk: medium
  TG Therapeutics, Inc. (CIK: 0001001316) filed an 8-K on February 28, 2024, reporting an event on the same date. This filing indicates the company is providing i
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Vanguard Group Maintains Significant Passive Stake in TG Therapeutics — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, indicating its ownership of TG Therapeutics Inc. common stock as of
• BlackRock Amends TG Therapeutics Stake, Signals Position Update — SC 13G/A · Jan 26, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of TG Therapeutics, Inc. common stock as of December 31, 2023. This amend
• State Street Corp Amends TG Therapeutics Stake, Remains Passive Investor — SC 13G/A · Jan 25, 2024
  State Street Corp, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of TG Therapeutics Inc common stock as
• TG Therapeutics Files 8-K on Material Definitive Agreement — 8-K · Jan 10, 2024
  TG Therapeutics, Inc. filed an 8-K on January 10, 2024, reporting an event that occurred on January 7, 2024, related to an entry into a material definitive agre

Risk Profile

Risk Assessment: Of TGTX's 21 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Tg Therapeutics, INC.'s most recent 10-Q filing (Nov 5, 2025):

• Revenue: $423.713M
• Net Income: $424.142M
• EPS: N/A
• Debt-to-Equity: 0.69
• Cash Position: $74.081M
• Operating Margin: 17.6%
• Total Assets: $1,025.024M
• Total Debt: $252.648M

Industry Context

TG Therapeutics operates in the highly competitive biotechnology and pharmaceutical sector, focusing on the development of novel treatments for cancer and autoimmune diseases. The industry is characterized by long development cycles, significant R&D investment, stringent regulatory oversight, and the potential for high rewards upon successful drug commercialization. Key trends include the increasing focus on targeted therapies, immunotherapies, and personalized medicine.

Top Tags

financials (7) · SEC Filing (5) · 10-Q (4) · operations (4) · amendment (4) · Pharmaceuticals (3) · 8-K (3) · corporate-governance (3) · TG Therapeutics (3) · institutional-ownership (3)

Key Numbers

• Product Revenue, Net: $417.815M — Increased from $206.381M in 2024 for the nine months, showing strong commercialization.
• Net Income: $424.142M — Significant increase from $0.052M in 2024 for the nine months, indicating profitability.
• Income Tax Benefit: $361.845M — Major contributor to net income for the nine months ended September 30, 2025.
• Operating Income: $72.830M — Increased from $11.980M in 2024 for the nine months, reflecting improved operational efficiency.
• Total Assets: $1,025.024M — Increased from $577.690M at December 31, 2024, indicating balance sheet growth.
• Cash and Cash Equivalents: $74.081M — Decreased from $179.894M at December 31, 2024, suggesting cash utilization despite revenue growth.
• Accounts Receivable, Net: $265.384M — Increased from $129.185M at December 31, 2024, reflecting higher sales.
• Deferred Tax Assets: $366.627M — New asset recognized as of September 30, 2025, contributing to total assets.
• Accumulated Deficit: $(1,105.052)M — Reduced from $(1,529.194)M at December 31, 2024, indicating progress towards sustained profitability.
• Shares Outstanding: 158,759,451 — As of October 31, 2025, relevant for per-share metrics.
• Product Revenue (H1 2025): $158.8M — Increased from $156.2M in H1 2024, showing growth.
• License Revenue (H1 2025): $761K — Increased from $367.9K in H1 2024, indicating strong licensing activity.
• Incremental Borrowing Rate: 10.25% — Used for older operating leases, impacting lease liabilities.
• NC Lease Borrowing Rate: 5.65% — Specific rate for the NC lease, affecting its present value.
• SEC File Number: 001-32639 — Identifies the company's filing with the SEC.

Forward-Looking Statements

• {"claim":"Vanguard will maintain a significant, passive stake in TG Therapeutics Inc. for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"high"}

Related Companies

BIIB · NVS · MRK

Frequently Asked Questions